Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClearPoint NeuroCLPT -1.54%63 EV-to-EBITDA is -18.84 as of Aug. 12, 2026. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review. Among 515 Medical Devices & Instruments companies, ClearPoint Neuro ranks worse than 194174.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ClearPoint Neuro's enterprise value is $481.78 Mil.
ClearPoint Neuro's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-25.57 Mil. Therefore, ClearPoint Neuro's EV-to-EBITDA for today is -18.84.
The historical rank and industry rank for ClearPoint Neuro's EV-to-EBITDA or its related term are showing as below:
CLPT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -102.14 Med: -12.4 Max: -0.56
Current: -18.84
During the past 13 years, the highest EV-to-EBITDA of ClearPoint Neuro was -0.56. The lowest was -102.14. And the median was -12.40.
CLPT's EV-to-EBITDA is ranked worse than 100% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.92
vs CLPT: -18.84
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ClearPoint Neuro's PE Ratio (TTM) for today is calculated as:
ClearPoint Neuro's share price for today is $14.66.
ClearPoint Neuro's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ClearPoint Neuro's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ClearPoint Neuro's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClearPoint Neuro EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's EV-to-EBITDA falls into.
ClearPoint Neuro's current Enterprise Value is $481.78 Mil.
ClearPoint Neuro's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (CLPT) has a EV-to-EBITDA of -18.84 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ClearPoint Neuro. According to the industry distribution chart, ClearPoint Neuro ranks #999999 out of 515 companies in the Medical Devices & Instruments industry.
Is ClearPoint Neuro's EV-to-EBITDA too high?
ClearPoint Neuro's current EV-to-EBITDA is -18.84. Based on the distribution chart, ClearPoint Neuro ranks #999999 out of 515 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's EV-to-EBITDA compare to SI and PACB?
According to the Medical Devices & Instruments industry distribution chart, ClearPoint Neuro ranks #999999 out of 515 companies for EV-to-EBITDA. This places ClearPoint Neuro in the lower half of its industry. The industry median EV-to-EBITDA is 14.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.92, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ClearPoint Neuro. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClearPoint Neuro's current EV-to-EBITDA is -18.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $14.66 — trading 3.7% above its estimated fair value. The current EV-to-EBITDA is -18.84. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current EV-to-EBITDA is -18.84 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClearPoint Neuro (CLPT) Overvalued in 2026?
Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued.
The current stock price of $14.66 is trading 3.7% above its estimated GF Value™ of $14.14.
GuruFocus considers ClearPoint Neuro to be Fairly Valued.
Key valuation signals for CLPT:
EV-to-EBITDA: -18.84
GF Value™: $14.14 vs. price of $14.66 (3.7% above fair value)
No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score
Get the complete analysis for CLPT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPT has been successfully added to your 
